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Aims 
The aim of this study was to examine the time to cessation of ADHD medication amongst 
young people with ADHD aged 16 in the period 2005-2013. 
Background 
Previous studies of prescribing in primary care reported high rates of medication cessation 
amongst 16 and 17 year olds with ADHD. The examination of trends since the introduction of 
new NICE guidance in 2008 will support service planning and improvement of outcomes 
over the vulnerable transition period from child to adult services. 
Methods 
We used primary care records from the Clinical Practice Research Datalink (CRPD) and 
identified cases prescribed ADHD medication at the time of their 16th birthday during the 
study period. The outcome was time to medication cessation from the age of 16. Cessation 
of medication was defined as occurring at the beginning of a gap of over six months in 
prescriptions.  
Results 
1,620 cases were included. The median time to cessation was 1.51 years (95% CI: 1.42 to 
1.67).The estimated probability of remaining on medication was 0.63 (95% CI: 0.61 to 0.65) 
at age 17 (i.e. at one year) and 0.41 (95% CI: 0.39 to 0.43) at age 18.  
Conclusions 
Young people with ADHD remain at high risk of cessation of medication during the transition 
from child to adult services. Despite the restriction that only primary care prescribing data 
were available, the results suggest continuing disparity between expected levels of symptom 
persistence and continuation of medication. 
 
Keywords: ADHD, psychopharmacology, prescribing, discontinuation, transition 
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Introduction 
The majority of young people with ADHD are likely to experience the persistence of 
symptoms beyond the age of 16. Faraone and colleagues’ review reported that up to 65% of 
those with the condition were likely to remain symptomatic at age 25, although only 15% met 
full diagnostic criteria at this age [1]. A recent systematic review of persistence suggested 
that 40-50% still met criteria for a diagnosis in adulthood where recommended methods such 
as age-appropriate symptom thresholds were used [2]. In contrast, studies of prescribing 
practices across Europe, the US and the UK report high rates of medication discontinuation 
in late adolescence, at a steeper and more rapid rate than the expected decline in symptoms 
[3-6]. 
In the UK, adolescents with ADHD are managed by child and adolescent mental health 
services or by paediatric services. Specialists in these clinics will initiate medication if 
required, but ongoing prescribing is usually carried out by the General Practitioner (GP) in 
primary care, under shared care arrangements. Young people move on from child services 
between the ages of 16 and 18, but historically there have often not been adult services 
available to those with ADHD to support ongoing prescribing. However, no UK study has to 
date examined prescribing over the transition period using data collected since the 
introduction of the UK National Institute for Health and Care Excellence (NICE) guidance in 
2008, which first recommended continuation of treatment for ADHD into adulthood if 
indicated [7]. Earlier studies of ADHD prescribing using primary care databases in the UK 
have covered the periods 1999-2006 in the Clinical Practice Research Datalink [5] and 2003-
2008 in the Health Improvement Network [6]. Over time, there has been increasing 
recognition of the challenges involved in the transition from child to adult services for young 
people with ADHD, which may include a lack of commissioned services, shared care 
arrangements and care pathways, and potentially the attitudes and knowledge of clinicians 
[8-13]. The ‘drop-off’ in prescribing seen in previous studies in late adolescence may 
therefore relate partially to these barriers to ongoing treatment over the transition period, as 
well as to patient choice and/or clinical judgement. In order to better understand recent 
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patterns and practice in prescribing for young people with ADHD in transition, we used the 
most recently available data on primary care prescribing in the Clinical Practice Research 
Datalink (from 2005 until the end of 2013) to study prescribing and describe the distribution 
of the time to cessation in young people with ADHD.  We also examine factors which might 
be associated with cessation of medication.  
 
Methods 
Study design 
We carried out a survival analysis of time to cessation of ADHD medication prescribed in 
primary care from the age of 16 in a cohort of patients from the Clinical Practice Research 
Datalink (CPRD). This age was chosen as it marks the beginning of the formal transition 
period in the UK from education and from children’s health services to adult provision, and 
would capture the period where cessation rates were highest in previous studies [5,6]. The 
CPRD is a large UK clinical database run by the Medicines and Healthcare products 
Regulatory Agency (MHRA). The primary care section contains the records of over 11 million 
patients and covers up to 6% of the population [14]. CPRD extracts anonymised data from 
participating GP practices’ IT systems. All prescriptions issued in primary care are 
automatically captured. Cases included in a research dataset must have a minimum duration 
of ‘up-to-standard’ data as defined by a metric examining continuity of recording by a 
practice and recording of events in a patient record. All protocols using patient-level data 
from the CPRD are reviewed and approved by the Independent Scientific Advisory 
Committee (ISAC) on behalf of the National Research Ethics Service Committee. This study 
protocol (13_213) was granted approval in 2013.  
 
Patients 
We obtained a dataset from CPRD containing the records of all patients who were aged 
between 10 and 20 in 2005, and had a diagnosis of ADHD coded in their file and/or at least 
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one prescription for an ADHD medication. Both were defined using a list of codes in the 
study protocol (available as supplementary material).  
From the cohort (n=9390), a subset of patients (n=1,620) met the criteria for the survival 
analysis, which were: 
• At least six months of consecutive prescriptions for an ADHD medication for the 
time period up to and including the 1st July of the year of their 16th birthday. A 
gap of up to six months between prescriptions was allowed. 
• At least one day of follow up data in the CPRD following their 16th birthday 
Patients were excluded if they had a gap in their registration with the practice for more than 
six months after their 16th birthday, meaning that follow-up data were not available. As 
CPRD does not provide the full date of birth, this was designated to be 1st July for each 
case, which minimised the error each way to a maximum of six months. As transition is a 
process, rather than a single event happening on a birthday, this did not affect the ability of 
the study to encompass the relevant time period of transition. The study period ran from 1st 
January 2005 until 31st December 2013. 
Analysis 
Stata version 13 was used to perform the survival analysis [15].The entry point was the 1st 
July in the year the patient turned 16. The observation period (time at risk) was then from 
this date until cessation or censoring (i.e., for as long as data were recorded for that patient) 
or the study period ended (31st December 2013). Cessation was defined as the beginning of 
a gap of more than six months in prescriptions for ADHD medication. In some cases, 
patients left practices which contribute data to the CPRD, and therefore their records were 
no longer included. Censoring occurred in the dataset where there were no further 
prescribing records for a case within the study period, and the outcome – i.e. whether and at 
what point cessation occurred, was unknown. Cases that were censored therefore are those 
who were still being prescribed medication up until the point of leaving a CPRD practice and 
being lost to follow-up. This was defined as having a prescription dated within 40 days of the 
date of being lost to follow-up through the CPRD. 
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We summarised the distribution of time to cessation using the Kaplan-Meier estimator. We 
fitted Cox regression models to explore variables recorded in CPRD which might predict 
cessation of ADHD medication (gender, prescription for another psychotropic medication at 
age 16 or over, referral to adult psychiatry at any point, diagnoses of anxiety or depression, 
conduct/oppositional defiant disorder or autistic spectrum disorder (ASD) at any point, 
learning disability, year of birth, smoking at any time, and time on ADHD medication before 
16th birthday). 
Each putative predictor variable was explored singly in crude (unadjusted) Cox regression 
models, reporting hazard ratios. All predictors with a p value less than 0.05 were then 
entered into a multivariable (adjusted) Cox regression model. We tested the proportional 
hazards assumption for each model by examining Schoenfeld residuals and plotting Nelson-
Aalen cumulative hazard estimates [16]. 
Sensitivity analyses were also carried out to assess the effect of excluding the cases 
censored before the end of the study from the analysis, and of extending the definition of 
censoring to include cases that had a prescription within 90 days of leaving a CPRD 
practice. 
Estimates from CRPD in 2012 prior to obtaining the dataset were that there would be 
approximately 1100 eligible individuals, with 80% having follow-up data available for eight or 
more years. Our power calculations suggested this sample size would be large enough to 
estimate the percentage of the cohort that remains on medication in adulthood with a margin 
of error no greater than +/-3.3 percentage points based on the width of the 95% confidence 
interval. 
Results 
Sample  
The analyses included 1,620 patients who met the criteria for entry, of which 1419 (87.6%) 
were male. The majority of cases (n=1230; 75.9%) experienced cessation during the follow-
up period. By the end of the study period, 302 patients were still prescribed medication and 
the remaining 88 were censored (i.e. they were lost to follow-up whilst still prescribed 
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medication). The censored cases were similar to the uncensored cases with respect to 
starting time, duration of medication and year of birth. 
Cessation of medication 
The median time to cessation was 1.5 years (95% CI 1.4 to 1.7), with the interquartile range 
of 0.7 years to 3.4 years. A Kaplan-Meier plot displays survival probabilities, which in this 
case is the cumulative probability of an individual remaining on medication (i.e., not 
experiencing the event of cessation) at any time after baseline, as shown in Figure 1. Table 
1 displays the probability of remaining on medication at one year time points from the age of 
16. At age 17, the probability of remaining on medication was 0.63 (95% CI: 0.61 to 0.65); at 
age 18 this was 0.41 (95% CI: 0.39 to 0.43). By age 19 years this had fallen further to 0.30 
(95% CI: 0.28 to 0.32). At age 22 years, only 39 cases remained on medication in the study, 
the rest were censored by reaching the end of the study period, no longer registered with a 
CPRD contributor practice, or had experienced cessation.  
Insert Table 1 and Figure 1 here 
Variables associated with cessation 
The results of the multivariable Cox regression analysis are presented in Table 2 below. 
Having a learning disability, an ASD diagnosis, and being referred to adult psychiatry at any 
point were associated with a lower likelihood of cessation, with a hazard ratio (HR) for 
cessation of 0.60 (95% CI 0.47 to 0.77), 0.68 (95% CI 0.55 to 0.83) and 0.67 (95% CI 0.54 to 
0.83) respectively. Cases with prescriptions of psychotropic medication at the age of 16 or 
were also less likely to experience cessation than those who had no such prescription 
recorded (HR 0.79, 95% CI 0.67 to 0.91). Having an ADHD prescription for three or more 
years prior to the age of 16 was also associated with a reduced likelihood of cessation of 
medication. Those born later in the cohort were marginally less likely to experience 
cessation compared with those born earlier between 1989 and 1992 (HR 0.88, 95% CI 0.77 
to 1.00), even after adjusting for all other variables (p=0.05).  
Insert Table 2 here 
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The p value for the global test of non-proportionality was 0.55, which suggested that the 
assumption of proportional hazards was reasonable. The planned sensitivity analyses to 
assess the effect of excluding the cases censored before the end of the study, and of 
extending the definition of censoring, did not appreciably alter the estimates obtained, and 
did not improve the fit of the model (details available on request). 
 
Discussion 
Time to cessation 
In our sample, the majority of participants prescribed medication at the age of 16 had 
stopped taking it two years later. The rate of cessation that we report remains greater than 
the estimated rate of decline of symptoms from epidemiological studies. Faraone et al.’s 
meta-analysis found the persistence of ADHD symptoms meeting the full criteria for the 
condition one year later to be 83%, whereas the probability of medication persistence in our 
study was 63%. Faraone et al. place the persistence of symptomatic ADHD at age 20 at 
69%, and a more conservative estimate of persistence of the full ADHD syndrome at 28%; 
both in excess of the probability of remaining on medication by age 20 in this study (21%) 
[1]. 
In contrast, Beau-Lejdstrom and colleagues analysed UK ADHD prescribing in under-16s 
between 1992 and 2013 and found that more than three-quarters of children were still taking 
medication after one year and 60% were still on medication after two years [17]. Our findings 
are more similar to estimates from McCarthy et al.’s earlier study where approximately 40% 
of those starting medication in childhood or adolescence remained on medication at age 18 
[6]. 
However, there is some evidence that prescribing patterns may be changing. Whilst a direct 
comparison should not be made with earlier studies, the populations are similar enough to 
note that our estimates of the rate of cessation from this analysis are slightly lower than 
those reported in the CADDY study, which covered the period from 1999 to 2006 [5]. 
Furthermore, those born later in our cohort who reached the age of 16 between 2009 and 
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2011 had a reduced hazard of cessation compared with those born earlier, with the lowest 
likelihood of cessation amongst those turning 16 in 2011.  These findings may reflect 
changing prescribing practice in the UK over the transition period, the development of adult 
services and an increasing acceptance that ADHD continues to merit pharmacological 
intervention after the age of 16, possibly influenced by guidance from NICE   in 2008 and the 
British Association for Psychopharmacology [7,18]. 
Predictors of cessation 
Being referred to adult psychiatry at any point was associated with a markedly reduced 
likelihood of medication cessation. This may reflect a greater willingness of GPs to continue 
prescribing ADHD medication with the specialist oversight recommended by guidelines [18]. 
It is also likely that such patients would have more severe or persistent ADHD symptoms, 
which would mean they were both more likely to be referred and to continue medication.  
The prescription of other non-ADHD psychotropic medication at the age of 16 or over was 
also associated with a reduced likelihood of medication cessation. This factor may be a 
marker for severity of ADHD or for other patient factors influencing help seeking behaviour 
and engagement with services [19]. We did not find an association between cessation and 
gender (unadjusted HR for females of 0.93; 95% CI 0.78 to 1.10), in contrast to the CADDY 
study [5]. This finding may have been influenced by the younger starting age in CADDY, or 
by secular changes. The gender distribution in our sample was in line with that from other 
studies of ADHD prescribing – 12% of our sample were female, compared to 15% in Beau-
Lejdstrom’s recent study [17] and 9% in the older CADDY study [5]. 
The only comorbid psychiatric diagnosis associated with a lower likelihood of cessation was 
ASD. Explanations for this finding are varied; people with ASD may be more likely to adhere 
to medication, or to experience greater impairment [20]. Due to their dual 
neurodevelopmental disorders they may also be managed in services such as paediatrics or 
learning disability, where transition may occur later or where there may be a greater 
acceptance of the use of medication. A similar explanation could apply to the association 
between learning disability and remaining on ADHD medication. 
10 
 
Strengths and limitations 
The chief strength of this analysis is the use of high quality and recent data from a national 
database capturing primary care prescribing until the end of 2013.The dataset covered a 
period which included the introduction of the NICE guidance on prescribing for adults and an 
expansion in awareness of adult ADHD. Use of shared care protocols means that in the UK, 
GPs undertake the majority of prescribing in ADHD, with specialist oversight [21]. 
Consequently, primary care prescriptions are likely to provide the fullest available picture of 
prescribing without using data linkages. Alternative sources such as dispensing records may 
offer more limited details on the diagnoses of the patient and other prescriptions which may 
be issued to them [10]. 
Nonetheless, primary care records will not capture prescriptions issued in specialist services 
which are not then passed on to primary care to continue, for example in shorter-term trials 
of medication, or highly severe and complex cases.  Where prescriptions are initiated 
outside primary care then transfer over to the GP, the length of time that an individual has 
been on medication may be underestimated, although the date of cessation (which was 
central to this analysis) would be unaffected. It is also important to consider that the outcome 
in this study was cessation of prescribing; some young people may not have been adherent 
to their medication and may have stopped taking it at an earlier date, if they took it at all [22]. 
With no standard definition of how long without prescribing constitutes ‘cessation’ of 
medication, we also had to decide upon a definition of cessation; the choice of a minimum 
six month period without prescribed medication was taken to allow for errors in estimating 
prescription length, medication breaks, and administrative delays. 
There were fewer than 200 individuals remaining in the survival analysis after four years of 
follow-up, with greater uncertainty around the probability of cessation beyond the age of 20.  
Subjects censored during the study period may also have affected the results if the 
censoring was informative. This could apply to individuals whose registration with a CPRD 
practice was terminated before the end of the study period and who were prescribed 
medication until the point that their registration finished. This termination of registration could 
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be related to moving away, which feasibly could be related to stopping medication, if it is not 
continued elsewhere. Alternatively, it could be due to moving to higher education and 
indicate a propensity to continue medication for the purpose of studying. Nonetheless, when 
these subjects were removed in a sensitivity analysis, there was no significant effect on the 
findings, suggesting minimal influence of informative censoring. 
The main limitation of using this primary care dataset was the lack of clinical detail coded in 
the records, such as measures of ADHD symptoms and severity.  It was not possible to 
determine for each case whether cessation took place due to remission of ADHD, patient 
choice, or ineffectiveness of medication; or whether it was due to service-related factors. 
Instead, the results should be considered in the light of other research into transition to 
provide context and explanations for exploration in future studies. 
Implications 
Despite the existence of guidance on the management of ADHD in young people in 
transition, research findings imply that these recommendations are not always implemented 
in UK clinical practice. Hall and colleagues report wide variation in the provision of services 
and in prescribing arrangements for people with ADHD in transition in England [10, 11]. 
Professionals also report a lack of confidence in prescribing for ADHD in over-18s [9,23,24]. 
Given these potential barriers to ongoing prescribing, it is therefore plausible that a 
proportion of the young people in our study may be stopping medication from which they 
could still benefit, and may therefore be at greater risk of experiencing the adverse outcomes 
associated with ADHD [25].  
The experiences of clinicians including paediatricians, psychiatrists and GPs are important 
both in understanding how these results reflect what is happening in everyday practice; and 
in considering how to target barriers and facilitators to optimising ADHD management in 
primary care and specialist services. Beliefs and knowledge will be influential in determining 
whether and how commissioners and clinicians implement the guidance on managing young 
people with ADHD in transition; and therefore warrant further investigation through interview 
or survey studies.  
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Prescribing for young adults will also be heavily influenced by transition pathways and by the 
availability of services where ADHD medication can be monitored. There are added 
complications due to the UK prescribing regulations on controlled ADHD drugs, which may 
be implemented differently across localities and create further complexity in commissioning 
and in shared care arrangements [18]. Furthermore, prescribing is only one part of the 
approach to managing young people with persisting ADHD symptoms.  There are various 
models of delivering care for older adolescents and adults with ADHD including extension of 
child mental health services, youth services and specific adult ADHD services, and recent 
recommendations on transition have been made by the UK Adult ADHD Network (UKAAN) 
[26,27,28]. However, the evidence regarding the effectiveness of different service models in 
improving outcomes needs to be strengthened - a systematic review in 2015 by Paul and 
colleagues concluded that there was currently no ‘high quality’ evidence to support the use 
of any particular transition care models [29]. Studies of adherence suggest that young adults 
may view stopping medication as an exertion of their autonomy, or may perceive that the 
negatives of medication outweigh the positive [22]. Consequently, there is a related question 
to be answered around what interventions or delivery models are most acceptable to young 
people, and would increase their engagement with managing their ADHD, and with services 
at this vulnerable time. 
In conclusion, we detected high levels of cessation of prescribing for young people reaching 
transition age, which in combination with epidemiological data suggest that some young 
people may be stopping pharmacological treatment when they could still benefit from it. 
Robust evaluation of the cost-effectiveness, outcomes and acceptability of different service 
configurations is therefore necessary and would support and inform investment by 
commissioners in an environment where resources are scarce. 
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Table 1: The cumulative probability of remaining on ADHD medication over time for 
cases prescribed ADHD medication at the age of 16 
Time from 16th 
birthday in 
years  
(age) 
N with a 
prescription 
for ADHD 
medication 
N stopping 
ADHD 
medication 
Probability of remaining 
on ADHD medication 
(also known as the survival 
function) 
(95% CI) 
0 (16 years) 1620 - 1 
1 (17 years) 1016 590 0.63 (0.61 to 0.65) 
2 (18 years) 646 343 0.41 (0.39 to 0.43) 
3 (19 years) 337 159 0.30 (0·28 to 0·32) 
4 (20 years) 165 91 0·21 (0.19 to 0.23) 
5 (21 years) 75 30 0.16 (0.14 to 0.19) 
6 (22 years) 39 11 0.13 (0.10 to 0.16) 
7 (23 years) 11 6 0.11 (0.08 to 0.14) 
8 (24 years) 11 0 0.11 (0.08 to 0.14) 
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Table 2: Factors associated with the probability of cessation of ADHD medication 
from age 16 onwards (taken from a fully adjusted multivariate Cox regression model) 
Variable Hazard ratio 
(the probability of 
experiencing 
cessation for those 
with this 
characteristic 
compared to those 
without) 
95% confidence 
interval for hazard 
ratio 
Other psychotropic 
prescription aged 16 
or over 
0.79 0.67 to 0.91 
Autism Spectrum 
Disorder 
0.68 0.55 to 0.83 
Learning disability 
0.60 0.47 to 0.77 
Referral to adult 
psychiatry 
0.67 0.54 to 0.83 
Smoking 
(ever recorded) 
1.10 0.98 to 1.24 
Birth year 1993-1995 
(vs 1989-1992) 
0.88 0.77 to 1.00 
Time on medication 
prior to 16th birthday: 
Less than 2 years 
2-3 years 
3 or more years 
 
 
 
 
Reference 
1.04 
0.81 
 
 
 
Reference 
0.89 to 1.21 
0.70 to 0.94 
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Figure 1: The probability of remaining on ADHD medication over time for young people 
prescribed medication at age 16 (Kaplan-Meier plot, shaded area represents 95% 
confidence intervals) 
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